FDA Grants Priority Review to Roche's Early-Stage Breast Cancer NDA
RHHBY's giredestrant as an adjuvant treatment for early-stage breast cancer won FDA Priority Review, backed by encouraging phase III data versus standard therap...
America Forever Bytes
Company
RHHBY's giredestrant as an adjuvant treatment for early-stage breast cancer won FDA Priority Review, backed by encouraging phase III data versus standard therap...
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared ...
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broa...
Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broa...